The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
BTOG 2019 | DDR proteins emerging as biomarkers and targets in lung cancer: the case of hSSB1
Presenting an array of work from his group in Brisbane on DNA damage repair proteins that are emerging as biomarkers and targets in lung cancer, Ken O’Byrne, MD, of the Princess Alexandra Hospital, Brisbane, Queensland, Australia, spoke to us about the context and application of this research. Prof. O’Byrne highlights hSSB1, discovered by his research partner Prof. Derek Richard, a highly conserved and important protein in the DNA damage repair process, and goes on to discuss the upcoming translation of this work into a clinical trial. This interview took place at the British Thoracic Oncology Group (BTOG) 2019 Annual Conference, held in Dublin, Ireland.
